公开(公告)号：US09353091B2

公开(公告)日：2016-05-31

申请号：US14260504

申请日：2014-04-24

Applicant: AbbVie Inc.

Inventor： David A. Betebenner ,  John K. Pratt ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Douglas K. Hutchinson ,  Warren M. Kati ,  Allan C. Krueger ,  Kenton L. Longenecker ,  Clarence J. Maring ,  John T. Randolph ,  Todd W. Rockway ,  Michael D. Tufano ,  Rolf Wagner ,  Dachun Liu

IPC: A61K31/503 ,  C07D409/10 ,  C07C311/08 ,  C07D207/27 ,  C07D213/64 ,  C07D233/32 ,  C07D233/72 ,  C07D239/10 ,  C07D239/54 ,  C07D263/22 ,  C07D275/02 ,  C07D403/10 ,  C07D405/10 ,  A61K31/18 ,  A61K31/27 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/513 ,  A61K45/06 ,  C07D263/24

CPC classification number: C07D409/10 ,  A61K31/18 ,  A61K31/27 ,  A61K31/402 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/425 ,  A61K31/4418 ,  A61K31/503 ,  A61K31/513 ,  A61K45/06 ,  C07C311/08 ,  C07D207/27 ,  C07D213/64 ,  C07D233/32 ,  C07D233/72 ,  C07D239/10 ,  C07D239/54 ,  C07D263/22 ,  C07D263/24 ,  C07D275/02 ,  C07D403/10 ,  C07D405/10 ,  Y02P20/55

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：US20160143916A1

公开(公告)日：2016-05-26

申请号：US15008994

申请日：2016-01-28

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John K. Pratt ,  Keith F. McDaniel ,  Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James H. Holms ,  Warren M. Kati ,  Dachun Liu ,  Robert A. Mantei ,  William J. McClellan ,  George S. Sheppard ,  Carol K. Wada

IPC: A61K31/541 ,  A61K45/06 ,  A61K31/5025 ,  A61K31/437 ,  A61K31/5377

CPC classification number: A61K31/541 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中A1，A2，A3，A4，X1，X2，Y1，L1，G1，Rx和Ry具有说明书中定义的任何值及其药学上可接受的盐 ，其作为治疗疾病和病症（包括炎性疾病，癌症和AIDS）的药剂是有用的。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US09994581B2

公开(公告)日：2018-06-12

申请号：US15103215

申请日：2014-12-10

Applicant: AbbVie Inc.

Inventor： Le Wang ,  Robin R. Frey ,  Todd M. Hansen ,  Dachun Liu ,  William J. McClellan ,  Keith F. McDaniel ,  John K. Pratt ,  Carol K. Wada

IPC: C07D491/22 ,  C07D491/056 ,  A61K45/06 ,  A61K31/4353 ,  C07D491/153

CPC classification number: C07D491/056 ,  A61K31/4353 ,  A61K45/06 ,  C07D491/153 ,  C07D491/22

Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20170157104A1

公开(公告)日：2017-06-08

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4178 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K45/06 ,  A61K31/4545

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20170015673A1

公开(公告)日：2017-01-19

申请号：US15103215

申请日：2014-12-10

Applicant: ABBVIE INC.

Inventor： Le Wang ,  Robin R. Frey ,  Todd M. Hansen ,  Dachun Liu ,  William J. McClellan ,  Keith F. McDaniel ,  John K. Pratt ,  Carol K. Wada

IPC: C07D491/056 ,  C07D491/153

CPC classification number: C07D491/056 ,  A61K31/4353 ,  A61K45/06 ,  C07D491/153 ,  C07D491/22

Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中Rx，X，Y，Y1，L1，A1，A2，A3，A4，A5，A6，A7和A8具有说明书中定义的任何值， 其药学上可接受的盐，其可用作治疗疾病和病症（包括炎性疾病，癌症和AIDS）的药剂。 还提供了由一种或多种式（I）化合物组成的药物组合物。

公开(公告)号：US09453007B2

公开(公告)日：2016-09-27

申请号：US14852984

申请日：2015-09-14

Applicant: AbbVie Inc. ,  Abbott Products GmbH

Inventor： Clarence J. Maring ,  John K. Pratt ,  William A. Carroll ,  Dachun Liu ,  David A. Betebenner ,  Douglas K. Hutchinson ,  Michael D. Tufano ,  Todd W. Rockway ,  Uwe Schoen ,  Axel Pahl ,  Andreas Witte

IPC: C07D413/14 ,  C07D413/04 ,  A61K31/5395 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07F7/18 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6558

CPC classification number: C07F7/1804 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5395 ,  A61K31/541 ,  A61K31/675 ,  A61K31/695 ,  A61K45/06 ,  B65D88/703 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07F9/65586 ,  F16K31/363 ,  Y10T137/86405 ,  Y10T137/86421

Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：US20130281450A1

公开(公告)日：2013-10-24

申请号：US13796731

申请日：2013-03-12

Applicant: AbbVie Inc.

Inventor： John K. Pratt ,  Dachun Liu ,  Chang H. Park ,  George S. Sheppard ,  Lisa A. Hasvold ,  Le Wang

IPC: C07D209/44 ,  C07D403/10 ,  C07D405/12 ,  C07D409/12 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/04 ,  C07D403/04 ,  A61K31/4184 ,  A61K31/404 ,  C07D209/48 ,  C07D405/10 ,  C07D401/12 ,  A61K31/4439 ,  A61K31/4709 ,  C07D403/12 ,  A61K31/416 ,  C07D417/12 ,  A61K31/427 ,  A61K31/4035

CPC classification number: C07D409/12 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/44 ,  C07D209/48 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D409/10 ,  C07D417/12

Abstract: The present invention provides for compounds of formula (I) wherein A, Y, J, R1, R2, and R3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.

Abstract translation: 本发明提供式（I）化合物，其中A，Y，J，R 1，R 2和R 3具有本说明书中定义的任何值及其药学上可接受的盐，其可用作治疗 疾病和病症，包括炎性疾病，糖尿病，肥胖症，癌症和艾滋病。 还提供了包含一种或多种式I化合物的药物组合物。

公开(公告)号：US20250084099A1

公开(公告)日：2025-03-13

申请号：US18638727

申请日：2024-04-18

Applicant: AbbVie Inc.

Inventor： Daniel Tzvi Cohen ,  Jane Gong ,  Tarun Jain ,  Puneet Kumar ,  Dachun Liu ,  Anthony Mastracchio ,  Mark Mills ,  Andrew William Phillips ,  John K. Pratt ,  Sreenivas Punna ,  Jennifer Ann Stockwell ,  Le Wang ,  Yiyun Yu

IPC: C07D513/04 ,  A61P35/00

Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20230312601A1

公开(公告)日：2023-10-05

申请号：US18192810

申请日：2023-03-30

Applicant: AbbVie Inc.

Inventor： Daniel Cohen ,  Jane Gong ,  Tarun Jain ,  Puneet Kumar ,  Dachun Liu ,  Anthony Mastracchio ,  Mark Mills ,  Andrew William Phillips ,  John K. Pratt ,  Sreenivas Punna ,  Jennifer Ann Stockwell ,  Le Wang ,  Yiyun Yu

IPC: C07D513/04 ,  A61P35/00

CPC classification number: C07D513/04 ,  A61P35/00

Abstract: The present disclosure provides for compounds of the general Formula (I)




wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20230158039A1

公开(公告)日：2023-05-25

申请号：US17810313

申请日：2022-06-30

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John K. Pratt ,  Keith F. McDaniel ,  Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James H. Holms ,  Warren M. Kati ,  Dachun Liu ,  Robert A. Mantei ,  William J. McClellan ,  George S. Sheppard ,  Carol K. Wada

IPC: A61K31/541 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06

CPC classification number: A61K31/541 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06

Abstract: The present invention provides for compounds of formula (I)






wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).